Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | SMPD3 | Q9NY59 | 6/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.41 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31441513 | 1.00 | MAP4K4 (0.53) | MAP4K4HDAC1NTRK1GPR119SMPD3 | |
| SCHEMBL31441655 | 0.87 | NR1H2 (0.49) | MAP4K4HDAC1NTRK1SMPD3SUV39H2 | |
| SCHEMBL15261397 | 0.83 | RET (0.52) | MAP4K4GPR119SMPD3SUV39H2RET | |
| SCHEMBL30172436 | 0.80 | NTRK1 (0.44) | NTRK1 | |
| SCHEMBL31383595 | 0.79 | MAP4K4 (0.58) | MAP4K4HDAC1GPR119SUV39H2SETD7 | |
| SCHEMBL31383652 | 0.79 | MAP4K4 (0.58) | MAP4K4HDAC1GPR119SUV39H2SETD7 | |
| SCHEMBL31441616 | 0.78 | SUV39H2 (0.56) | MAP4K4SUV39H2 | |
| SCHEMBL15280693 | 0.78 | SUV39H2 (0.56) | MAP4K4SUV39H2 | |
| SCHEMBL4573301 | 0.78 | MAP4K4 (0.58) | MAP4K4HDAC1GPR119SUV39H2SETD7 | |
| SCHEMBL8117492 | 0.78 | MAP4K4 (0.58) | MAP4K4HDAC1GPR119SUV39H2SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| WO-2025054448-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | MAP4K4 82/4885HDAC1 1551/4885NTRK1 1008/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | MAP4K4 75/4885HDAC1 1375/4885NTRK1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.